TW201725212A - 特異性於降鈣素基因相關胜肽的新穎蛋白 - Google Patents

特異性於降鈣素基因相關胜肽的新穎蛋白 Download PDF

Info

Publication number
TW201725212A
TW201725212A TW105140113A TW105140113A TW201725212A TW 201725212 A TW201725212 A TW 201725212A TW 105140113 A TW105140113 A TW 105140113A TW 105140113 A TW105140113 A TW 105140113A TW 201725212 A TW201725212 A TW 201725212A
Authority
TW
Taiwan
Prior art keywords
leu
lys
ser
glu
tyr
Prior art date
Application number
TW105140113A
Other languages
English (en)
Chinese (zh)
Inventor
加布里埃爾 馬欽內爾
克莉絲汀 羅特
亞歷山大 維登曼
哈齊達西哈姆 貝萊巴
馬龍 漢納
安德烈 阿勒施托費爾
布拉德利 倫德
窪田一史
牧野充裕
高橋咲子
橋本隆二
高橋亘
大豊衛
Original Assignee
第一三共股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 第一三共股份有限公司 filed Critical 第一三共股份有限公司
Publication of TW201725212A publication Critical patent/TW201725212A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
TW105140113A 2015-12-10 2016-12-05 特異性於降鈣素基因相關胜肽的新穎蛋白 TW201725212A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562265792P 2015-12-10 2015-12-10

Publications (1)

Publication Number Publication Date
TW201725212A true TW201725212A (zh) 2017-07-16

Family

ID=57758561

Family Applications (1)

Application Number Title Priority Date Filing Date
TW105140113A TW201725212A (zh) 2015-12-10 2016-12-05 特異性於降鈣素基因相關胜肽的新穎蛋白

Country Status (8)

Country Link
US (2) US10400016B2 (enExample)
EP (1) EP3387009A1 (enExample)
JP (1) JP7050676B2 (enExample)
CN (1) CN109071621B (enExample)
AU (1) AU2016367207B2 (enExample)
CA (1) CA3006914A1 (enExample)
TW (1) TW201725212A (enExample)
WO (1) WO2017097946A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012013662B1 (pt) 2009-12-07 2022-08-02 Pieris Pharmaceuticals Gmbh Muteínas de lipocalina associada à gelatinase de neutrófilo humano (lcn2, hngal), seu uso e seus métodos de geração e produção, molécula de ácido nucleico, célula hospedeira, composição farmacêutica e kit de diagnóstico ou analítico
EP2920202B1 (en) 2012-11-19 2018-08-29 Pieris Pharmaceuticals GmbH Novel specific-binding polypeptides and uses thereof
EP3145945B1 (en) 2014-05-22 2020-07-15 Pieris Pharmaceuticals GmbH Novel specific-binding polypeptides and uses thereof
SG11201705278QA (en) 2015-01-28 2017-07-28 Pieris Pharmaceuticals Gmbh Novel proteins specific for angiogenesis
RU2727165C2 (ru) 2015-05-04 2020-07-21 ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ Слитый полипептид с противораковой активностью
DK3298030T5 (en) 2015-05-18 2024-10-07 Pieris Pharmaceuticals Gmbh Anti-cancerfusionspolypeptid
TW201725212A (zh) 2015-12-10 2017-07-16 第一三共股份有限公司 特異性於降鈣素基因相關胜肽的新穎蛋白
US20230182041A1 (en) * 2018-04-25 2023-06-15 Medimmune, Llc Purification of antibodies
KR101991207B1 (ko) * 2018-11-29 2019-06-19 씨제이제일제당 (주) cAMP 수용 단백질 변이체 및 이를 이용한 L-아미노산 제조방법
CN113939307A (zh) 2019-03-29 2022-01-14 皮里斯制药有限公司 脂质运载蛋白突变蛋白的吸入施用
US20230205917A1 (en) * 2021-12-24 2023-06-29 BeeKeeperAI, Inc. Systems and methods for data validation and transformation of data in a zero-trust environment
CN120827617A (zh) * 2024-04-19 2025-10-24 中国人民解放军军事科学院军事医学研究院 一种促进抗体生成及疫苗保护的方法和用途

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2032831T5 (es) 1986-08-19 2001-02-16 Genentech Inc Dispositivo y dispersion para suministro intrapulmonar de factores de crecimiento polipeptidos y citoquinas.
JPH01215289A (ja) 1988-02-22 1989-08-29 Toa Nenryo Kogyo Kk 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法
FR2649991B2 (fr) 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
US5728553A (en) 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
AU696387B2 (en) 1994-05-18 1998-09-10 Inhale Therapeutic Systems, Inc. Methods and compositions for the dry powder formulation of interferons
DE4417598A1 (de) 1994-05-19 1995-12-14 Max Planck Gesellschaft Verwendung des Tetracyclinpromotors zur stringent regulierten Produktion von rekombinanten Proteinen in prokaryontischen Zellen
WO1996023879A1 (en) 1995-01-30 1996-08-08 Terrapin Technologies, Inc. Glubodies - multiplicities of proteins capable of binding a variety of small molecules
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
DE19641876B4 (de) 1996-10-10 2011-09-29 Iba Gmbh Streptavidinmuteine
WO1998016873A1 (en) 1996-10-14 1998-04-23 Firm Forsat Ltd. Method for preparing dispersions of chromogenic components
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
CA2233725A1 (en) 1998-03-31 1999-09-30 Hemosol Inc. Hemoglobin-hydroxyethyl starch complexes
JP3839667B2 (ja) 1998-06-08 2006-11-01 エフ．ホフマン−ラ ロシュ アーゲー 慢性Ｃ型肝炎の処置のためのＰｅｇ−ＩＮＦ−アルファ及びリバビリンの使用
US6403564B1 (en) 1998-10-16 2002-06-11 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
DE19926068C1 (de) 1999-06-08 2001-01-11 Arne Skerra Muteine des Bilin-Bindungsproteins
US7211395B2 (en) 2001-03-09 2007-05-01 Dyax Corp. Serum albumin binding moieties
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
US7118915B2 (en) 2001-09-27 2006-10-10 Pieris Proteolab Ag Muteins of apolipoprotein D
US7691970B2 (en) 2003-08-25 2010-04-06 Pieris Ag Muteins of a bilin-binding protein with affinity for a given target
WO2005019255A1 (en) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of tear lipocalin
JP2007284351A (ja) 2004-07-27 2007-11-01 Osaka Bioscience Institute アミロイド蛋白質の凝集を抑制する物質とその作用
US7892827B2 (en) 2004-11-26 2011-02-22 Pieris Ag Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
AU2006294644A1 (en) 2005-09-27 2007-04-05 Amunix, Inc. Proteinaceous pharmaceuticals and uses thereof
EP2225268B1 (en) 2007-10-19 2012-08-29 Abbott Laboratories Immunoassays and kits for the detection of ngal
US8420051B2 (en) 2008-06-24 2013-04-16 Technische Universitaet Meunchen Muteins of hNGAL and related proteins with affinity for a given target
WO2010054025A1 (en) * 2008-11-05 2010-05-14 Abbott Laboratories Neutrophil gelatinase-associated lipocalin (ngal) protein isoforms enriched from urine and recombinant chinese hamster ovary (cho) cells and related compositions, antibodies, and methods of enrichment, analysis and use
BR112012013662B1 (pt) 2009-12-07 2022-08-02 Pieris Pharmaceuticals Gmbh Muteínas de lipocalina associada à gelatinase de neutrófilo humano (lcn2, hngal), seu uso e seus métodos de geração e produção, molécula de ácido nucleico, célula hospedeira, composição farmacêutica e kit de diagnóstico ou analítico
AU2011263786B2 (en) * 2010-06-08 2014-11-13 Astrazeneca Ab Tear lipocalin muteins binding IL-4 R alpha
AU2011290751B2 (en) 2010-08-16 2015-08-13 Pieris Ag Binding proteins for Hepcidin
CA2817779C (en) 2010-11-15 2019-02-19 Pieris Pharmaceuticals Gmbh Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3)
PT3495392T (pt) * 2011-05-20 2021-09-22 H Lundbeck As Composições anti-cgrp e a sua utilização
EP2920202B1 (en) * 2012-11-19 2018-08-29 Pieris Pharmaceuticals GmbH Novel specific-binding polypeptides and uses thereof
EP2925337B1 (en) * 2012-11-21 2019-07-03 The Trustees of Columbia University in the City of New York Mutant ngal proteins and uses thereof
MX378344B (es) 2014-03-21 2025-03-10 Teva Pharmaceuticals Int Gmbh Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos.
US10556945B2 (en) * 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
WO2015176017A1 (en) 2014-05-16 2015-11-19 Salk Institute For Biological Studies Compositions and methods for treating metabolic disorders
SG11201705278QA (en) 2015-01-28 2017-07-28 Pieris Pharmaceuticals Gmbh Novel proteins specific for angiogenesis
EP3259282A1 (en) 2015-02-18 2017-12-27 Sanofi Novel proteins specific for pyoverdine and pyochelin
PH12017501583B1 (en) 2015-05-04 2023-01-20 Pieris Pharmaceuticals Gmbh Novel proteins specific for cd137
EP3298029A1 (en) 2015-05-18 2018-03-28 Pieris Pharmaceuticals GmbH Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3)
TW201725212A (zh) 2015-12-10 2017-07-16 第一三共股份有限公司 特異性於降鈣素基因相關胜肽的新穎蛋白

Also Published As

Publication number Publication date
WO2017097946A1 (en) 2017-06-15
CA3006914A1 (en) 2017-06-15
JP2019506140A (ja) 2019-03-07
CN109071621A (zh) 2018-12-21
US11034737B2 (en) 2021-06-15
US20170166615A1 (en) 2017-06-15
US10400016B2 (en) 2019-09-03
JP7050676B2 (ja) 2022-04-08
AU2016367207B2 (en) 2021-04-01
US20190338002A1 (en) 2019-11-07
AU2016367207A1 (en) 2018-06-14
EP3387009A1 (en) 2018-10-17
CN109071621B (zh) 2023-03-28

Similar Documents

Publication Publication Date Title
US11034737B2 (en) Proteins specific for calcitonin gene-related peptide
US11034738B2 (en) Nucleic acid molecules encoding human neutrophil gelatinase-associated lipocalin (hNGAL) which bind angiopoietin-2 (Ang-2)
JP6884708B2 (ja) Ｃｄ１３７に特異的なタンパク質
US9260492B2 (en) Muteins of human lipocalin 2 with affinity for glypican-3 (GPC-3)
US10703810B2 (en) Fusion polypeptides which bind vascular endothelial growth factor a (VEGF-A) and angiopoietin-2 (Ang-2)
CN107660211A (zh) 新的对绿脓菌荧光素和绿脓菌螯铁蛋白特异性的蛋白质
CN107787327A (zh) 对磷脂酰肌醇聚糖‑3（gpc3）具有亲和力的人脂质运载蛋白2的突变蛋白